Clinical trials · New York, NY
Metastatic Head and Neck Squamous Cell Carcinoma clinical trials in New York
We’re tracking 46 recruiting metastatic head and neck squamous cell carcinoma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
New York, New YorkAges 18 years+ - NCT06163534Recruiting
Biomarker profiling study for advanced head and neck cancer patients
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
New York, New YorkAges 18 years+ - NCT02734537RecruitingPhase 2
Radiation with or without cisplatin after head and neck surgery
This trial studies whether adding cisplatin (a chemotherapy medicine) to radiation therapy helps people with stage III–IVA squamous cell cancer of the head and neck after they’ve had surgery. It’s meant to lower the risk of the cancer coming back.
New York, New YorkAges 18 years+ - NCT05419089RecruitingPhase 2
Testing robotic surgery for HPV-related throat cancer patients
This Phase 2 trial studies a robotic surgery approach for certain HPV-related throat cancers, using HPV blood tests before and after surgery to guide care. If your cancer is HPV-related and your HPV blood test results match the trial targets, you may be able to join and help improve treatment for future patients.
New York, New YorkAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
New York, New YorkAges 18 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
New York, New YorkAges 18–130 - NCT04333537RecruitingPhase 2/Phase 3
Sentinel node biopsy versus standard neck surgery for early mouth cancer
This trial compares two ways of checking whether early oral cavity squamous cell cancer has spread to neck lymph nodes. It tests whether sentinel lymph node biopsy can find spread as well as standard neck dissection, while potentially reducing more extensive surgery for some people.
New York, New YorkAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
New York, New YorkAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
New York, New YorkAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
New York, New YorkAges 18 years+ - NCT05376553Enrolling by invitationPhase 1
Test cemiplimab plus chemo before treatment for head and neck cancer
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
New York, New YorkAges 18 years+ - NCT06021626RecruitingPhase 1
Study of CRD3874-SI for advanced solid tumors
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New York, New YorkAges 18 years+ - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
New York, New YorkAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
New York, New YorkAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
New York, New YorkAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
New York, New YorkAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
New York, New YorkAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
New York, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
New York, New YorkAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
New York, New YorkAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+
Hear when a new Metastatic Head and Neck Squamous Cell Carcinoma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Metastatic Head and Neck Squamous Cell Carcinoma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting metastatic head and neck squamous cell carcinoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- NYU Langone Health · 6 studies
- Icahn School of Medicine at Mount Sinai · 4 studies
- Memorial Sloan Kettering Basking Ridge · 3 studies
- Memorial Sloan Kettering Bergen · 3 studies
- Memorial Sloan Kettering Commack · 3 studies
- Memorial Sloan Kettering Monmouth · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
What taking part in a metastatic head and neck squamous cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic head and neck squamous cell carcinoma studies in New York.
Common questions
- Are there metastatic head and neck squamous cell carcinoma clinical trials near New York?
- Yes. We're currently tracking 46 recruiting metastatic head and neck squamous cell carcinoma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic head and neck squamous cell carcinoma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic head and neck squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic head and neck squamous cell carcinoma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.